Acetyl-CoA represents a central node of carbon metabolism that plays a key role in bioenergetics, cell proliferation, and the regulation of gene expression. Highly glycolytic or hypoxic tumors must produce sufficient quantities of this metabolite to support cell growth and survival under nutrient-limiting conditions. Here, we show that the nucleocytosolic acetyl-CoA synthetase enzyme, ACSS2, supplies a key source of acetyl-CoA for tumors by capturing acetate as a carbon source. Despite exhibiting no gross deficits in growth or development, adult mice lacking ACSS2 exhibit a significant reduction in tumor burden in two different models of hepatocellular carcinoma. ACSS2 is expressed in a large proportion of human tumors, and its activity is responsible for the majority of cellular acetate uptake into both lipids and histones. These observations may qualify ACSS2 as a targetable metabolic vulnerability of a wide spectrum of tumors.
INTRODUCTION
Cell growth and proliferation are intimately coordinated with metabolism. Potentially distinct differences in metabolism between normal and cancerous cells have sparked a renewed interest in targeting metabolic enzymes as an approach to the discovery of new anticancer therapeutics. The metabolic strategies utilized by cancer cells to enhance proliferative capacity under nutrient-limiting conditions remain controversial and poorly understood. It has thus been unclear as to which aspects of cell metabolism might represent a realistic, targetable vulnerability of tumors relative to normal cells and tissues.
We recently found that prototrophic yeast cells monitor intracellular levels of acetyl-CoA in order to commit to a new round of cell division Shi and Tu, 2013) . Acetyl-CoA is a key intermediate of carbon sources, which not only fuels ATP production via the TCA cycle, but also functions as an essential building block for the synthesis of fatty acids and sterols. When yeast cells commit to cell division, they significantly enhance the production of acetyl-CoA. Elevated levels of acetyl-CoA induce acetylation of histones on a set of more than 1,000 genes critical for cell growth . This battery of ''growth genes'' includes virtually all genes important for ribosome biogenesis, protein translation, and amino acid biosynthesis. Transcription of the key G1 cyclin (CLN3) that gates entry of yeast cells into the cell division cycle is also dependent upon the ability of cells to substantially enhance the intracellular abundance of acetyl-CoA (Shi and Tu, 2013) . Thus, in budding yeast, acetyl-CoA is a sentinel metabolite that regulates transcription of growth genes via epigenetic modification of chromatin Kaelin and McKnight, 2013) .
The strict dependence of yeast cells on acetyl-CoA for cell growth and proliferation prompted us to examine whether acetyl-CoA might also be rate limiting for mammalian cell growth. In well-fed mammalian cells, the acetyl-CoA used for lipid synthesis and histone acetylation is primarily supplied by mitochondrially derived citrate (Srere, 1959; Wellen et al., 2009 ). This metabolite is enzymatically converted into acetylCoA via ATP citrate lyase (ACLY) (Srere, 1959; Srere and Lipmann, 1953) . Cells grown under the nutrient-unlimited conditions of tissue culture medium also make acetyl-CoA via citrate consumption. By contrast, the nutrient-limiting conditions of tumor growth in animals and humans bring into question what pathways might be primarily utilized for acetyl-CoA production. The phenomenon of aerobic glycolysis famously characterized by Otto Warburg described the truncation of glucose oxidation at pyruvate (Warburg, 1956a (Warburg, , 1956b . Instead of pyruvate being transported into mitochondria for conversion into acetyl-CoA by the pyruvate dehydrogenase complex, many cancer cells are highly glycolytic and preferentially convert pyruvate into lactate. If pyruvate fails to enter the TCA cycle in cancer cells, how is it that sufficient citrate is made for ACLY-mediated production of acetyl-CoA?
Several groups have recently demonstrated the conversion of glutamine into acetyl-CoA via the phenomenon of reductive carboxylation whereby the TCA cycle can be modified to run in reverse (Le et Figure S1 (mean ± SD, n = 3).
(legend continued on next page) 2012; Mullen et al., 2012; Wise et al., 2011) . Whereas evidence supportive of reductive carboxylation has been obtained in studies of cancer cells grown in tissue culture, in vivo studies of primary human glioblastomas (GBMs) to date have revealed little or no catabolism of glutamine (Marin-Valencia et al., 2012) . These GBMs instead exhibit substantive mitochondrial oxidation and a net synthesis of glutamine from glucose. Thus, the ability of glutamine to function as a source of acetyl-CoA in native tumors remains unclear. These perplexing observations led us to consider alternative sources of acetyl-CoA for tumors in which, as a result of highly glycolytic or hypoxic metabolic environments, glucose-derived pyruvate is preferentially shunted toward lactate instead of acetyl-CoA. Budding yeast lack ATP citrate lyase and instead rely on a family of enzymes called acetyl-CoA synthetases (De Virgilio et al., 1992; Takahashi et al., 2006; van den Berg et al., 1996) . Acetyl-CoA synthetases catalyze the synthesis of acetyl-CoA from acetate and CoA in an ATP-dependent reaction (Berg, 1956; Jones et al., 1953; Lipmann and Tuttle, 1945) . We hypothesized that the mammalian versions of these acetyl-CoA synthetase enzymes might help cancer cells produce acetyl-CoA from acetate under the challenging growth conditions of solid tumors. Consistent with this idea, acetate could rescue histone acetylation in cell lines in which ACLY was knocked down, although the physiological relevance of acetate in mammalian cells was questioned (Wellen et al., 2009 ). However, a role for acetate in fueling tumor growth is supported by positron emission tomography (PET) imaging studies using [
11 C]acetate wherein numerous clinical studies have documented avid acetate uptake in prostate, lung, liver, and brain cancers (Ho et al., 2003; Nomori et al., 2008; Oyama et al., 2002; Tsuchida et al., 2008 (Yoshii et al., 2009a (Yoshii et al., , 2009b Yun et al., 2009 ). In the accompanying article by Mashimo et al (2014) in this issue of Cell, acetate consumption by human tumors was recently confirmed by nuclear magnetic resonance (NMR) facilitated [ 13 C]acetate metabolic tracer experiments. Here, we report evidence that the nucleocytosolic ACSS2 enzyme is of critical importance for mammalian cells to utilize acetate as a source of acetyl-CoA, and that mice lacking this enzyme exhibit a substantial reduction in tumor burden in two genetic models of liver cancer.
RESULTS

ACSS2 Is Required for Acetate Uptake and Utilization in Mammalian Cells
The mammalian genome contains genes encoding three different enzymes capable of catalyzing the ATP-dependent synthesis of acetyl-CoA from acetate (Watkins et al., 2007) . Two such enzymes, designated ACSS1 and ACSS3, are mitochondrial proteins (Fujino et al., 2001; Pé rez-Chacó n et al., 2009) . The third, designated ACSS2, has been reported to be localized to both the cytoplasmic and nuclear compartments of mammalian cells (Ariyannur et al., 2010; Luong et al., 2000) . In order to assess the relative contributions of these enzymes for cellular utilization of acetate for either lipid synthesis or histone acetylation, RNAi agents were deployed to selectively silence their respective production. After having observed substantive, RNAi-mediated suppression of ACSS1, ACSS2, and ACSS3 ( Figure S1 available online), cells were exposed to 14 Clabeled acetate in order to measure incorporation of acetyl units into either lipids or histones. RNAi-mediated suppression of ACSS2 led to a more significant diminution in both lipid and histone assimilation of radiolabeled acetate than suppression of ACSS1 or ACSS3 ( Figures 1A and 1B) .
In order to pursue these observations in a more rigorous manner, mouse embryonic fibroblasts (MEFs) were prepared from embryos of mice bearing inactivating mutations in both alleles of ACSS2 (ACSS2 À/À ). Littermate embryos heterozygous for the ACSS2 mutation (ACSS2 À/+ ), and wild-type littermates (ACSS2 +/+ ), were also used to prepare MEFs ( Figure S1 ). As a third means of testing the importance of ACSS2 for acetate uptake into mammalian cells, a high-throughput screen was conducted in search of chemical inhibitors of the enzyme. Purified, recombinant human ACSS2 enzyme was screened against roughly 200,000 drug-like chemicals housed within the UTSW compound file. The details of this screen are presented in the Experimental Procedures. Among hundreds of primary hits cross-screened for reversibility, dose-responsive potency, and selectivity with respect to inhibition of medium-and longchain coenzyme-A-dependent acyl-CoA synthetase enzymes, a small molecule quinoxaline having an IC 50 of $0.6 mM in biochemical assays, and $5 mM in its ability to inhibit cellular (E) ACSS2 is druggable. A high-throughput screen was conducted to identify small molecule inhibitors of the human ACSS2 enzyme (Experimental Procedures). The structure of one of the most potent and specific inhibitors, 1-(2,3-di(thiophen-2-yl)quinoxalin-6-yl)-3-(2-methoxyethyl)urea, is shown. This quinoxaline compound inhibited the ability of HepG2 cells to incorporate [
14 C]acetate into lipids with IC 50 = 6.8 mM (mean ± SEM, n = 3).
(F) The quinoxaline was also able to inhibit HepG2 utilization of [ 14 C]acetate for histone acetylation with IC 50 = 5.5 mM (mean ± SEM, n = 3). Figure S1 . For each cell line, uptake amount was normalized against control (mean ± SD, n = 3 Figure S1 ). The fact that a selective chemical inhibitor of ACSS2 substantially inhibits acetate incorporation into both lipids and histones further confirms the importance of this enzyme for cellular uptake of acetate.
As a final test of the importance of ACSS2 for acetate uptake, small hairpin RNA (shRNA)-mediated attenuation of ACSS2 was tested on four different cancer cell lines, including LL/2, PC3, U2OS, and Hep3B ( Figure S1 ). In all four cancer cell lines, attenuation of ACSS2 led to a significant impediment to [
14 C]acetate uptake into both lipids and histones ( Figures 1G and 1H ). The combination of shRNA-mediated mRNA knockdown approaches, studies of MEFs selectively mutated at the ACSS2 locus, and the identification of a selective chemical inhibitor of ACSS2 provide strong evidence that this particular enzyme is primarily responsible for allowing mammalian cells to convert acetate into acetyl-CoA for subsequent metabolic utilization.
Reduced Tumor Formation in ACSS2-Deficient Mice
As a means of testing the contribution of ACSS2 to tumorigenesis, we introduced the ACSS2-null allele into a strain of genetically engineered mice that develop liver cancer due to expression of a liver-specific, doxycycline (dox)-regulated transgene encoding the SV40 early region (ApoE-rtTA M2 :TRE2-TAg; herein referred to as TAg). Notably, adult ACSS2-null mice display no overt phenotypic deficits and both sexes are fertile. Cohorts of male and female TAg mice with and without ACSS2 were generated as described in Experimental Procedures and provided with drinking water supplemented with 10 mg/ml doxycycline for 42-45 days (Table S1 ). This regimen promotes reproducible and robust multifocal tumor development in a background of hepatic hyperplasia (Comerford et al., 2012) . Post-sacrifice, livers were scored for tumor development using a nonlinear tumor-burden scale based on the number and size of visible tumors on the surface of the liver, percentage of liver/body weight, and the relative amount of tumor-free liver as described in detail (Table S2) . After 42-45 days of dox treatment, livers of ACSS2 +/+ :TAg mice were covered with small-to medium-sized tumors reflecting multifocal tumor growth in response to sustained expression of the SV40 large T and small t (LT/st) oncoproteins. Twenty of 21 mice (95%) exhibited tumor burden scores of 8 or greater ( Figure 2A ). By contrast, only 48% of ACSS2 À/À :TAg mice exhibited tumor growth of an equivalent magnitude, with almost half (41%) receiving scores of 6 or lower. The statistical significance in the overall reduction in mean tumor burden score from 9.4 to 6.8 in mice with and without ACSS2 achieved a calculated p value of 0.0002 ( Figure 2A ). Given that tumor burdens within the 9-10 range and 6-7 range reflected the presence of 100-200 tumors (too many to accurately count) or 20-50 tumors, respectively, these data indicate that ACSS2 deficiency reduces the absolute number of liver tumors by at least 4-fold.
Having shown that loss of ACSS2 correlates with reduced tumor burdens in the TAg liver cancer model, we next asked what impact of loss of ACSS2 might have on the development of tumors driven by c-Myc overexpression and loss of PTEN, both of which are associated with human hepatocarcinogenesis (Kawate et al., 1999; Peng et al., 1993; Yao et al., 1999) . In this genetically engineered mouse model, liver-specific expression of c-Myc (Sandgren et al., 1989) , in conjunction with hepatic deletion of the PTEN tumor suppressor (PTEN lox/lox ) (Lesche et al., 2002) , promotes the development of at least two large tumors (>10 mm) per liver in a background of hepatomegaly in 90% of mice at 6-7 months of age (S.A.C. and R.E.H., unpublished data). This second liver cancer model, herein referred to as c-Myc:DPTEN, constitutes a more stochastic and clinically relevant model of hepatic tumor development than the SV40 TAg model. Cohorts of male and female c-Myc:DPTEN mice with and without ACSS2 were generated as described in Experimental Procedures and sacrificed at 6-7 months of age. Livers were scored for tumor development using a scale that differed from the one used to score the TAg tumors to accommodate the more stochastic pattern of tumor development in these mice (Table S2) . At 6-7 months of age, 20/24 (83%) of ACSS2 +/+ :cMyc:DPTEN mice had livers with at least ten visible tumors (2-15 mm in size), resulting in assignment of tumor burden scores of 7 or greater ( Figure 2B ). This was in direct contrast to cohorts of agematched ACSS2 À/À :c-Myc:DPTEN mice in which only 6/21 mice (29%) had tumor burdens of 7 or greater. Indeed, ACSS2 deficiency not only reduced the mean tumor burden score from 7.8 to 4.7 (p < 0.0001), but inhibited tumor growth to such an extent that 71% of ACSS2-deficient mice had livers with fewer than ten small tumors, or no tumors at all ( Figure 2B ).
Immunohistochemical Studies of ACSS2 Expression in Hepatocellular Tumors in Mice
Our results showing that the loss of ACSS2 reduced liver tumor development in two different mouse models suggested that a subset of tumors might be dependent on ACSS2 for growth and therefore express high levels of ACSS2. To determine if this was the case, we surveyed the distribution of ACSS2 protein expression in normal mouse liver and in tumor-bearing livers from both cancer models by performing immunohistochemistry (IHC) with an ACSS2-specific antibody. In livers of WT mice, ACSS2 was highly expressed in the cytoplasm and nucleus of hepatocytes in periportal zones 1 and 2 with virtually no expression evident in centrilobular zone 3 or in bile ducts ( Figure 3A) . Moreover, livers of ACSS2-null mice were devoid of any immunoreactivity indicating absolute specificity of the antibody for ACSS2 and lack of any cross-reactivity with ACSS1, ACSS3, or other acyl-CoA synthetase enzymes ( Figure 3A ). The expression of ACSS2 in tumors from the TAg and c-Myc:DPTEN mice showed significant heterogeneity both between and within individual tumors ( Figure 3A ). Approximately 56% of TAg and 75% of c-Myc:DPTEN tumors contained ACSS2-positive cells (Table S3) , whereas the remainder contained none. Given that ACSS2-positive tumors varied with respect to the proportion of ACSS2-expressing cells, a scoring method was devised to classify tumors as ACSS2 , whereas the remainder were ACSS2 LOW (Table S3) . In several tumors, focal areas of prominent nuclear ACSS2 staining were seen, suggesting that enhanced translocation of ACSS2 from the cytoplasm to the nucleus might be associated with tumorigenesis, although this was not a universal finding. Importantly, evaluation of ACSS2 expression in c-Myc:DPTEN livers, where tumors were juxtaposed to areas of liver in which normal hepatic zonation had been maintained, showed that the level of ACSS2 expressed in ACSS2 HIGH tumors was comparable to that found in normal periportal hepatocytes, suggesting that ACSS2 expression was maintained, rather than induced, in a subset of tumors, and was lost in others. As expected, tumor-bearing livers from ACSS2-deficient TAg or c-Myc:DPTEN mice were devoid of any immunoreactivity.
Having shown that the loss of ACSS2 reduced tumor incidence in both liver cancer models, we next determined if ACSS2 deficiency altered the tumor spectrum. Comparative histological analysis of hematoxylin-and-eosin-stained sections of tumor-bearing livers of ACSS2 +/+ and ACSS2 À/À TAg and c-Myc:DPTEN mice showed that ACSS2 deficiency increased the proportion of well-differentiated HCCs at the expense of moderately and poorly differentiated HCCs and other tumor types in both models ( Figure S2 ), suggesting that ACSS2 drives the emergence of more aggressive hepatic tumors in the mouse.
Immunohistochemical Studies of ACSS2 Expression in Human Tumors
Clinical imaging studies have observed avid [ 11 C]acetate uptake in a wide spectrum of human cancers, including prostate, liver, lung, and brain tumors (Ho et al., 2003; Nomori et al., 2008; Oyama et al., 2002; Tsuchida et al., 2008) . It has been proposed that acetate uptake in these tumors might reflect expression of the acetyl-CoA synthetase enzymes, including ACSS2 (Yoshii et al., 2009b; Yun et al., 2009) . In normal adult mice, ACSS2 mRNA is most abundantly expressed in liver Table S1 for mouse genotyping details and Table S2 :c-Myc:DPTEN mice with tumor burden scores of R7 at 6-7 months of age (20/24 (83%) and 6/21 (29%), respectively). See also Figure S2 . and kidney, with lower levels present in the heart, brain, and testis (Luong et al., 2000) . We next surveyed the extent of ACSS2 protein expression in a variety of human tumor samples by immunohistochemical staining of commercially available tumor tissue microarrays. Significant ACSS2 expression was observed in a substantial number of human breast, ovarian, and lung tumor samples ( Figure 3B ). Normal, noncancerous samples of the tissues of origin exhibited little to no ACSS2 protein at all.
We then surveyed ACSS2 expression in a well-annotated set of human triple-negative breast cancers (Figures 4A and S3 ).
Immunohistochemical analysis was available for 154 cases after discounting loss of cores due to sectioning and IHC processing. Expression was stratified into three categories for association with overall survival. High expression of ACSS2 (H-score 120-300) was associated with shorter overall survival compared to ACSS2-negative cases (p = 0.03) ( Figure 4B ). However, the observed correlation between ACSS2 expression and decreased survival does not necessarily imply dependency. Expression of ACSS2 was observed predominantly in the cytoplasm with some cases exhibiting significant nuclear staining. Taken together, these observations strongly suggest that Table S5. ACSS2 is expressed to a significant extent in particular tumor types, including triple-negative breast cancers. Figures 5A-5D ). Tracer pharmacokinetics appeared to reach a state of equilibrium between 25 and 40 min after radiotracer administration, as depicted in the time-activity curves (TAC) ( Figure 5E ). During this time interval, radiotracer concentration within the tumor region-of-interest (ROI) was nearly three times greater in tumors arising in the c-Myc:DPTEN mice compared to uptake in normal liver. Presence of tumor was confirmed histologically and exhibited significant staining of ACSS2 ( Figure 5F ). Figure S3 . (B) High expression of ACSS2 was associated with poorer overall survival (p = 0.03).
compared to WT ( Figure S4 ). Collectively, these observations demonstrate a strong correlation between [ 11 C]acetate uptake and ACSS2 expression.
DISCUSSION
Here, we describe experiments indicating that certain tumors may have acquired a dependency on acetate as a carbon source for the production of acetyl-CoA. This conclusion is, for many reasons, perplexing. Unlike the low millimolar levels of blood glucose, which is a considerably more energetic carbon source than acetate, blood level measurements for acetate are estimated at $20-50 mM (Psychogios et al., 2011; Tollinger et al., 1979) . How could an energy-diminished metabolite, relative to glucose, feed tumors when its abundance in blood is two orders of magnitude lower than glucose? Before offering possible explanations to this conundrum, it may be of value to compare the evolution of human tumors to the work of Richard Lenski and colleagues on bacterial evolution (Blount et al., 2012) . By continually growing cultures of E. coli for upward of 25 years, Lenski and colleagues have evolved derivatives that outcompete the starting bacterial cells via enhanced cell growth rates in the range of 70%. Some of Lenski's cultures were found to have achieved enhanced growth via the induction of pathways facilitating the catabolism of citrate. We offer the hypothesis that during the evolution of certain tumors, a Lenski-like adaptation may have taken place-not to citrate dependence, but to acetate dependence.
In support of this idea, we offer the following considerations. [ 11 C]acetate PET imaging studies have shown that many human cancers avidly take up acetate, and confirmatory [
13 C]acetate NMR tracer studies also reveal selective acetate uptake in human tumors (Mashimo et al., 2014) . Moreover, substantive ACSS2 immunohistochemical staining of both hepatic tumors in mice and numerous tumors from humans reveals strong expression of the enzyme (Figures 3 and 4) . Indeed, we observe a strong correlation between ACSS2 expression and uptake of [ 11 C]acetate into liver tumors in mice ( Figure 5 ). As shown here, for mammalian cells ACSS2 is the most important member of this enzyme family for uptake of acetate and its conversion into lipids and acetylated histones (Figure 1) . Last, animals bearing targeted mutations in both alleles of the ACSS2 gene show a substantially diminished tumor burden in two genetic models of cancer (Figure 2 ). We simplistically conclude that certain tumors are able to avidly capture acetate to help fuel their growth and survival (Figure 6 ). If normal cells and tissues are far less competent in acquiring and retaining acetate, then tumors may be able to survive and grow by avid consumption of this suboptimal hydrocarbon fuel. Studies of prototrophic yeast grown continuously in a chemostat offer a framework for thinking about how mammalian tissues might share acetate. When grown at high density under continuous, glucose-limitation conditions, yeast cells enter into a robust metabolic cycle in which a population of yeast cells synchronously oscillates (Tu et al., 2005) . During glycolytic growth, cells consume glucose and ferment the carbon source all the way to ethanol. By contrast, during respiratory growth, ethanol is retrieved as a carbon source via its sequential anabolic conversion into acetaldehyde, acetate, and acetyl-CoA. Indeed, the periodic secretion and uptake of ethanol and acetate can be observed as a function of the yeast metabolic cycle (Tu et al., 2005) , revealing that these simple products of glycolysis can be secreted and then shared among subpopulations of the community.
We offer the speculative idea that acetate is liberally moved in and out of mammalian cells and tissues in a dynamic fashion. Because acetate is not typically thought to be a physiologically significant carbon source in mammals, what are the possible sources of acetate? The half-life of acetyl modifications on histones has been measured to be on the order of only $2-3 min as a result of the opposing actions of histone acetyltransferase and deacetylase enzymes (Jackson et al., 1975; Waterborg, 2002) . Histone proteins are among the most abundant in cells, and several dozen sites within each histone octamer are subject to modification by acetylation (Shahbazian and Grunstein, 2007) . Considering the extremely short half-life of acetylation modifications, substantial quantities of acetate could be continuously released from histone tails simply as a result of deacetylation. Moreover, if certain tumor cells liberally secrete lactate via the truncation in glycolysis discovered by Otto Warburg, neighboring normal cells could convert lactate back into pyruvate, thereby yielding a possible source of acetylCoA. Acetyl-CoA hydrolase or thioesterase enzymes could rebalance metabolism such that acetate could be liberated from normal cells as a hydrocarbon source for rogue consumption by tumor cells. In other words, if a tumor cell were hardwired to exist in an acetate-capturing or fixing state, it might significantly outcompete the rest of the human body in its ability to feed upon a suboptimal carbon source present at relatively low concentrations.
At the cost of a single ATP, one acetate molecule can be retrieved to produce acetyl-CoA for use in the synthesis of fatty acids or sterols, for the acetylation of histones, or for further oxidation via the TCA cycle to generate an additional $12 units of ATP (Figure 6 ). Acetate can also be used for the synthesis of the amino acid glutamate (Mashimo et al., 2014) . Unlike yeast, mammals lack a glyoxylate cycle and therefore cannot utilize acetate for the synthesis of glucose. Nonetheless, the ability to recoup acetate for any of these other purposes stands to promote tumor cell growth or survivability in the face of nutritionally challenging or hypoxic microenvironments. In contrast, acetate might be irrelevant for nutritionally replete cells or tissues. Given ample supplies of glucose, coupled with the ability to convert glucose into acetyl-CoA via citrate spilling out of mitochondria, normal cells or tissues might actually represent net producers of acetate, rather than net consumers.
Were it indeed the case that certain tumors acquire, via expression of ACSS2, a strict dependency on acetate for their growth or survival, then selective inhibitors of this nonessential enzyme might represent an unusually ripe opportunity for the development of new anticancer therapeutics. By screening a library of 200,000 drug-like chemicals, we have discovered compounds that are capable of selectively inhibiting ACSS2 relative to other acyl-CoA synthetase enzymes that ligate coenzyme A onto medium or long chain fatty acids. It is hoped that these chemical inhibitors of ACSS2 can be optimized for potency, selectivity, and pharmacological properties. If the normal human cells and tissues are not heavily reliant on the activity of the ACSS2 enzyme, it is possible that such agents might inhibit the growth of ACSS2-expressing tumors with a favorable therapeutic window.
EXPERIMENTAL PROCEDURES
Construction of Stable Knockdown Cell Lines
Cells were seeded in 60 mm dishes to 30% confluence the day before infection. Fresh medium (1 ml) and retrovirus (1 ml; treated with 8 mg/ml polyberen) carrying shRNA against ACSS1, ACSS2, ACSS3, or REN (Renilla luciferase) as control were added during virus infection. Puromycin was added at 2 mg/ml to the medium for selection at 48-60 hr after infection. Medium was replaced with fresh medium supplemented with puromycin every 1 or 2 days. Cells were split as they became confluent. Puromycin was maintained in the medium for selection up to 10 days. The following are the sequences of shRNA used.
shREN: AGGAATTATAATGCTTATCTA shACSS1: CCAGTTAAATGTCTCTGTCAA shACSS2: CAGGATTGATGACATGCTCAA shACSS3: GCCGTTGATCGTCATATTGAA .0], 1 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT) with protease inhibitors and then subjected to one freeze/thaw cycle at À20 C. Lysates were centrifuged at 4 C 10,000 3 g for 10 min. Supernatants were discarded, and the pellets were resuspended in 400 ml 0.4 N H 2 SO 4 and vortexed until pellets were dissolved. The lysates were rotated at 4 C overnight and then centrifuged at 4 C 16,000 3 g for 10 min. Supernatants were taken and counted for radioactivity.
Mouse Tumorigenesis Experiments and Scoring of Tumor Burdens
Generation of mice and liver tumorigenesis experiments are described in detail in the Supplemental Information. All experiments were approved by the University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee. Tumor burden scores were assigned on the basis of the number and size of tumors, the magnitude of hepatic hyperplasia, and the amount of tumor-free liver remaining after 42-45 days of dox treatment (TAg model) or at 6-7 months of age (c-Myc:DPTEN model). A detailed description of criteria used to assign tumor burden scores in each model is provided in Table S2 . Scores were assigned by S.A.C. or R.E.H.
Scoring of ACSS2 Expression in Tumors
Tumor scoring for ACSS2 expression was conducted by performing IHC with the ACSS2-specific antibody on formalin fixed paraffin-embedded sections of liver from TAg mice provided with dox for 42-45 days and from 6-to 7-month-old c-Myc:DPTEN mice. Each slide contained sections cut from a block containing a minimum of six randomly selected pieces of liver collected All invasive carcinomas were graded according to the method described by Elston and Ellis (1991) . The tissue microarrays (TMAs) were constructed as previously described using a tissue arrayer (Beecher Instruments). Two tissue cores (0.6 mm diameter) were sampled from each block and transferred to the recipient TMA block. All ACSS2-stained slides were scanned using the ScanScope System (Aperio Technologies) and viewed using ImageScope software (Aperio). Pathologist with subspecialty training in breast pathology (A.K.W.) assured that areas selected for automated image analysis represented tumor. Staining intensity was graded with: none as 0, weak as 1+, moderate as 2+, and marked as 3+. The percentage of stained tumor cells was recorded. H-score was calculated as previously described using the following formula (1 3 % of weak staining) + (2 3 % moderate staining) + (3 3 % marked staining). Duplicates of cores were scored separately, and the highest-yielding H-score among the three constructs was selected.
Data and associations were assessed using the R-statistical package. Kaplan-Meier survival curves were used to estimate overall survival, which was defined as the time from date of surgery to date of death from TNBC or to the last follow-up date for censored cases. The log-rank test was performed to compare survival between groups. A p value < 0.05 was considered significant.
High-Throughput Screen to Identify Inhibitors of Human ACSS2
Human ACSS2 enzyme was expressed in insect cells using the Invitrogen Bac to Bac expression system. Acetyl-CoA (C4780) and pyrophosphatase (I1643) were purchased from Sigma. CellTiter-Glo was purchased from Promega. EnzChek Pyrophosphate Assay Kit (E6645), which includes purine nucleotide phosphorylase (PNP) and MESG, was purchased from Life Technologies.
ACSS2 converts ATP, acetate, CoA into AMP, pyrophosphate, and acetylCoA. In our assay, the reaction was monitored by the disappearance of ATP using a luciferase-based CellTiter-Glo reagent. The screen was carried out using 384-well plates. A typical reaction mixture contained 0.1 mM CoA, 0.02 mM ATP, 10 mM DTT, 0.1 unit/ml pyrophosphatase, 1 mg/ml ACSS2, 0.1 mg/ml BSA, 150 mM NaCl, 1 mM MgCl 2 , and 50 mM HEPES (pH 7.5). The reaction was initiated by the addition of 5 ml of 25 mM sodium acetate to each well containing 20 ml reaction mixture. The plates were then spun for 1 min at 1,500 3 g and incubated at 37 C. When the reaction reached 70% completion, which typically occurred after 2.5-5 hr, 25 ml CellTiter-Glo reagent was added to each well. The plates were shaken for 2 min, and luminescence was read on a PerkinElmer Envision plate reader. The presence of an inhibitor slowed down the consumption of ATP and was revealed by high luminescence reading on the plate reader. We identified 1,152 hits in the primary screen of 220K compounds in our chemical library at UTSW. By removing redundant hits in the large structure groups, we cherry-picked 926 hits for further confirmation using the same assay but carried out in triplicate. We were able to confirm 118 of the 926 hits. To test the specificity of the inhibitors, we carried out a counterscreen against ACSF2 (medium chain fatty acid-CoA synthetase) and ACSL5 (long chain fatty acid-CoA synthetase). We were able to identify 62 compounds as specific inhibitors against ACSS2 based on their nonactivity against ACSF2 and ACSL5. One of these most potent and specific inhibitors N-(2,3-di-2-thienyl-6-quinoxalinyl)-N 0 -(2-methoxyethyl)urea was purchased from ChemBridge and retested ( Figures 1E and 1F ).
Biochemical Measurement of IC 50 of Inhibitors
The measurement of initial rate is ideally carried out when the reaction extent is less than 15%. The variation in the luciferase assay used in the HTS screen is typically around 10%. For this reason, we adopted a different assay for the measurement of reaction rate in the determination of IC 50 of ACSS2 inhibitors.
Instead of monitoring the consumption of ATP, we measured generation of pyrophosphate in a coupled enzymatic assay. The reaction mixture contained pyrophosphatase, which converts pyrophosphate to phosphate, and purine nucleotide phosphorylase (PNP), which couples phosphate with a nucleotide analog (MESG), resulting in a compound that absorbs light at 360 nm. A typical reaction mixture includes 50 mM CoA, 100 mM ATP, 5 mM sodium acetate, 0.2 mM MESG, 0.2% BSA, 20 nM ACSS2, 0.4 mM PNP, 1 unit/ml of yeast pyrophosphatase, 1 mM MgCl 2 , 150 mM NaCl, and 50 mM HEPES (pH 7.5).
The reaction rates were computed by the increase of absorption at 360 nm for a range of inhibitor concentrations. 
